Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
May 06, 2019 01:27 ET
|
H. Lundbeck A/S
Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the...
Lundbeck held its Annual General Meeting on 26 March 2019 at the company’s registered office
March 26, 2019 09:16 ET
|
H. Lundbeck A/S
Valby, Denmark, 26 March 2019 - H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting. The...
Lundbeck afholdt ordinær generalforsamling den 26. marts 2019 på selskabets hjemsted
March 26, 2019 09:16 ET
|
H. Lundbeck A/S
Valby, Danmark, 26. marts 2019 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at bestyrelsens beretning blev taget til efterretning og årsrapporten blev godkendt på generalforsamlingen. ...
Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer
March 08, 2019 03:00 ET
|
H. Lundbeck A/S
Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy &...
Lundbeck udnævner Keld Flintholm Jørgensen til koncerndirektør, Chief Business Officer
March 08, 2019 03:00 ET
|
H. Lundbeck A/S
Valby, Danmark, 8. marts 2019 - H. Lundbeck A/S (Lundbeck) annoncerede i dag udnævnelsen af Keld Flintholm Jørgensen til Chief Business Officer (CBO). Keld skal stå i spidsen for Corporate Strategy...
Notice of Annual General Meeting
February 28, 2019 03:15 ET
|
H. Lundbeck A/S
Valby, Denmark, 28 February 2019 – Notice is hereby given of the Annual General Meeting of H. Lundbeck A/S to be held on: Tuesday 26 March 2019 at 10:00 am The general meeting will...
Indkaldelse til ordinær generalforsamling
February 28, 2019 03:15 ET
|
H. Lundbeck A/S
Valby, Danmark, 28. februar 2019 – Der indkaldes herved til ordinær generalforsamling i H. Lundbeck A/S. tirsdag den 26. marts 2019 kl. 10:00 Generalforsamlingen afholdes på...
Lundbeck increases its share capital by 5,631 shares (0.0028 % of outstanding shares) as a result of exercise of employee warrants
February 18, 2019 03:46 ET
|
H. Lundbeck A/S
Valby, Denmark, 18 February 2019 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 28,155 as a consequence of the exercise of employee warrants. ...
Kapitalforhøjelse i Lundbeck med 5.631 aktier (0,0028 % af udestående aktier) som følge af warrant-program for medarbejdere
February 18, 2019 03:46 ET
|
H. Lundbeck A/S
Valby, Danmark, 18. februar 2019 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 28.155 som følge af udnyttelsen af medarbejder-warrants. ...
Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
February 14, 2019 09:00 ET
|
H. Lundbeck A/S
The efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with bipolar I disorder was investigated in two three-week, double-blind,...